Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 38 Carcinoma, Non-Small-Cell Lung 23 Stomach Neoplasms 19 Nasopharyngeal Carcinoma 19 Triple Negative Breast Neoplasms 18 Esophageal Squamous Cell Carcinoma 17 Esophageal Neoplasms 16 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 8 Sarcoma 6 Recurrence 6 Neoplasm Metastasis 6 Melanoma 6 Liver Neoplasms 6 Cholangiocarcinoma 6 Lung Neoplasms 5 Hodgkin Disease 5 Biliary Tract Neoplasms 5 Osteosarcoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Advanced Gastric Cancer 4 Rectal Neoplasms 3 Nasopharyngeal Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Urinary Bladder Neoplasms 2

Interventions

sintilimab 1 camrelizumab 1 Thoracic Surgery, Video-Assisted 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Multiple Primary Lung Cancer × camrelizumab × Clear all

NCT05053802 2021-09-23

MAGIC

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

Multiple Primary Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡